ReviewFrontiers in pharmacology2019
Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?
Review in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.International journal of molecular sciences · 2022Pooled it
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options.Molecular biomedicine · 2026Review
- Role of Exosome in Solid Cancer Progression and Its Potential Therapeutics in Cancer Treatment.Cancer medicine · 2025Review
- Circulating Microvesicles Enriched in miR-126-5p and miR-223-3p: Potential Biomarkers in Acute Coronary Syndrome.Biomedicines · 2025Article
- Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.Current opinion in hematology · 2025Review
- Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota.International journal of biological sciences · 2025Review
- The role of protease-activated receptors (PARs) in the functioning of platelets and platelet-derived microparticles (PMPs).Frontiers in molecular biosciences · 2025Review
- Feature Paper in Oral Physiology and Pathology.Life (Basel, Switzerland) · 2024Article
- Platelet, Antiplatelet Therapy and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Life (Basel, Switzerland) · 2024Review
- Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells.Molecular diversity · 2024Article
- Systematic review and bioinformatics analysis of plasma and serum extracellular vesicles proteome in type 2 diabetes.Heliyon · 2024Article
- Cryptogenic ischemic stroke in cardiac transthyretin amyloidosis and sinus rhythm: a case report.Frontiers in cardiovascular medicine · 2024Article
- Emerging Role of Tumor-Educated Platelets as a New Liquid Biopsy Tool for Colorectal Cancer.Archives of Iranian medicine · 2023Review
- Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.Journal of neuroimmunology · 2023Review
- Inflammatory processes involved in NASH-related hepatocellular carcinoma.Bioscience reports · 2023Review
- Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells.Cancers · 2023Article
- Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Wound Healing.Life (Basel, Switzerland) · 2022Review
- Platelet-Derived Exosomes in Atherosclerosis.International journal of molecular sciences · 2022Review
- Platelet-Derived Extracellular Vesicles Stimulate Migration through Partial Remodelling of the CaCells · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-derived large extracellular vesicles (often referred to as microparticles in the field of cardiovascular disease) have been identified as effector in the atherothrombotic process, therefore representing a target of pharmacological intervention of potential interest. Despite that, limited evidence is so far available concerning the effects of antiplatelet agents on the release of platelet-derived extracellular vesicles. In the present narrative review, the mechanisms leading to vesiculation in platelets and the pathophysiological processes implicated will be discussed. This will be followed by a summary of the present evidence concerning the effects of antiplatelet agents under experimental conditions and in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.